Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Apr;180(4):894-901.
doi: 10.1111/bjd.17421. Epub 2019 Jan 15.

Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy

Z Z N Yiu  1   2 , C Sorbe  3 , M Lunt  4 , S J Rustenbach  3 , L Kühl  3 , M Augustin  3 , K J Mason  1 , D M Ashcroft  2 , C E M Griffiths  1 , R B Warren  1 ; BADBIR Study Group
Collaborators, Affiliations
Multicenter Study

Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy

Z Z N Yiu et al. Br J Dermatol. 2019 Apr.

Abstract

Background: Patients with psoriasis are often concerned about the risk of serious infection associated with systemic psoriasis treatments.

Objectives: To develop and externally validate a prediction model for serious infection in patients with psoriasis within 1 year of starting systemic therapies.

Methods: The risk prediction model was developed using the British Association of Dermatologists Biologic Interventions Register (BADBIR), and the German Psoriasis Registry PsoBest was used as the validation dataset. Model discrimination and calibration were assessed internally and externally using the C-statistic, the calibration slope and the calibration in the large.

Results: Overall 175 (1·7%) out of 10 033 participants from BADBIR and 41 (1·7%) out of 2423 participants from PsoBest developed a serious infection within 1 year of therapy initiation. Selected predictors in a multiple logistic regression model included nine baseline covariates, and starting infliximab was the strongest predictor. Evaluation of model performance showed a bootstrap optimism-corrected C-statistic of 0·64 [95% confidence interval (CI) 0·60-0·69], calibration in the large of 0·02 (95% CI -0·14 to 0·17) and a calibration slope of 0·88 (95% CI 0·70-1·07), while external validation performance was poor, with C-statistic 0·52 (95% CI 0·42-0·62), calibration in the large 0·06 (95% CI -0·25 to 0·37) and calibration slope 0·36 (95% CI -0·24 to 0·97).

Conclusions: We present the first results of the development of a multivariable prediction model. This model may help patients and dermatologists in the U.K. and the Republic of Ireland to identify modifiable risk factors and inform therapy choice in a shared decision-making process.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram depicting the participant selection numbers of the development dataset (British Association of Dermatologists Biologic Interventions Register, BADBIR) and the validation dataset (PsoBest).
See this image and copyright information in PMC

References

    1. Wakkee M, de Vries E, van den Haak P et al Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population‐based cohort. J Am Acad Dermatol 2011; 65:1135–44. - PubMed
    1. Thorneloe RJ, Griffiths CEM, Emsley R et al Intentional and unintentional medication non‐adherence in psoriasis: the role of patients’ medication beliefs and habit strength. J Invest Dermatol 2018; 138:785–94. - PMC - PubMed
    1. Burden AD, Warren RB, Kleyn CE et al The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): design, methodology and objectives. Br J Dermatol 2012; 166:545–54. - PubMed
    1. Augustin M, Spehr C, Radtke MA et al German psoriasis registry PsoBest: objectives, methodology and baseline data. J Dtsch Dermatol Ges 2014; 12:48–57. - PubMed
    1. Ormerod AD, Augustin M, Baker C et al Challenges for synthesising data in a network of registries for systemic psoriasis therapies. Dermatology 2012; 224:236–43. - PubMed

MeSH terms

Substances